Altimmune (ALT) stock
Follow ALT's trial news. Members get an alert when Altimmune files news, and see its trials, share raises, and its CEO's filings.
What's next for ALT, and how long its cash lasts
From Altimmune’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 17 quarters
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why ALT scores -3
PoorTrending down, 1 of 14 checks firingWhat the Quality Score means
- +1Momentum traits 1 of 14 firing right now, one point each
- −3Long-term trend below a falling 200-day, down over one year, down over two years
- Profit subtracts
What's next
Wed Sep 30: Stifel Virtual Cardiometabolic…Investor conference · date confirmed.
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed -4.3% on average, higher 1 of 4 times.
What would turn ALT's score around: 5 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
ALT has 1 of 14 checks firing
One per group is shown here.
How ALT ranks in Biotech
ALT is #194 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
RGEN9/1421
ABCL10/1420
XERS9/1419
HALOOpen for its score
ONCOpen for its score
ALT1/14-3
When does ALT report, and what happens after?
Expected to report Thu Nov 5, before the open (in 37 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026Before open | Before open | +1.7% | -2.3% | -1.0% |
| May 13, 2026Before open | Before open | -3.3% | -1.9% | -11.0% |
| Mar 5, 2026Before open | Before open | -4.0% | -17.9% | -11.0% |
| Nov 6, 2025Before open | Before open | +1.9% | +5.1% | +12.8% |
Who is trading ALT
Insiders
One insider bought $44K across 1 filing in the last 6 months. No open-market sales on record. The newest:
About Altimmune
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of ALT's score, with the points and the reason
- All 14 checks on ALT and on all 2,950 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ALT
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.